CEL-SCI Corporation (CEL-SCI) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 2007.
Business Overview: CEL-SCI is a biotechnology company focused on developing cancer immunotherapies. Its lead product, Multikine, is an "Immune SIMULATOR" designed as a first-line treatment for advanced primary head and neck cancer. In January 2007, the FDA concurred with the initiation of a global Phase III clinical trial for Multikine. The company also holds pre-clinical technology called L.E.A.P.S., with a lead product (CEL-1000 peptide) showing protection against various diseases in animal models.
Operational Status: The company has no commercial product revenue and relies on equity financing, debt, and grants to fund operations. It is currently in the clinical development phase.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 |
|---|---|---|
| Grant Revenue | $57,043 | $125,457 |
| Net Loss | $(9,629,657) | $(7,939,210) |
| Net Loss Per Share (Basic) | $(0.10) | $(0.10) |
| Research & Development Expenses | $2,528,528 | $1,896,976 |
| General & Administrative Expenses | $6,704,538 | $3,406,775 |
| Cash and Cash Equivalents (End of Period) | $10,993,021 | $8,080,365 |
| Working Capital | $10,257,568 | $7,109,879 |
| Total Liabilities | $6,060,703 | $10,583,878 |
| Stockholders' Equity | $14,670,099 | $(930,601) |
Debt: As of September 30, 2007, the outstanding principal on Series K convertible notes was $3,285,715. The notes bear interest at the greater of 8% or LIBOR + 3% and are due in 2011. Significant derivative liabilities related to these notes and warrants were recorded on the balance sheet.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $1.69 million (21%) compared to 2006, driven primarily by higher operating expenses and interest costs, partially offset by a gain on derivative instruments.
- Revenue Decline: Grant revenue decreased by approximately $68,400 due to the completion of a grant in March 2007.
- Expense Increases:
- R&D: Increased by ~$631,600 due to new CEL-1000 projects and preparation for Phase III trials.
- G&A: Increased by ~$3.3 million, primarily due to public relations, strategic consulting, and accounting expenses related to the valuation of Series K notes and warrants.
- Derivative Gains: The company recognized a gain of $868,182 on derivative instruments in 2007, compared to $2.33 million in 2006. These gains/losses are non-cash and result from marking convertible debt and warrants to fair value based on stock price volatility.
- Equity Position: Stockholders' equity turned positive ($14.7 million) from a deficit in 2006, largely due to a $15 million private placement of common stock in April 2007.
Guidance, Outlook, and Risks
Outlook: Management believes current cash resources are sufficient to satisfy anticipated requirements for the next 12 months (through fiscal 2008). The company plans to use existing resources and proceeds from warrant exercises to fund operations. Substantial additional funds will be required to complete the Phase III clinical trial and subsequent regulatory approval.
Capital Requirements: The company has no assurance that additional financing will be available on favorable terms. Without regulatory approval, the company cannot generate product revenue.
Key Risks and Contingencies:
- Derivative Accounting Volatility: Future financial statements are expected to show significant gains and losses on derivative instruments due to the requirement to mark convertible debt to market value based on stock price fluctuations.
- Manufacturing Lease: In August 2007, the company leased a 73,000 sq. ft. facility in Baltimore for manufacturing. The 20-year lease requires annual base rent of $1.575 million (escalating 3% annually) plus taxes, insurance, and maintenance. The company paid $3.15 million toward remodeling costs.
- Convertible Debt Terms: The Series K notes contain anti-dilution provisions. If the company sells stock below the conversion price, the price is lowered. Failure to maintain a registration statement for conversion shares could trigger liquidated damages.
- Regulatory Approval: Success depends on the outcome of the Phase III trial, which must demonstrate a 10% improvement in overall survival to be considered successful.
Investor Verification Checklist
- Cash Runway: Verify if the $11 million cash balance is sufficient to cover the $1.575 million annual lease obligation and Phase III trial costs without immediate dilution.
- Derivative Liability Exposure: Assess the impact of stock price volatility on the $5.6 million total fair value of convertible debt and related warrants, which can cause significant non-cash earnings swings.
- Phase III Trial Progress: Confirm the enrollment status and preliminary data of the global Phase III trial for Multikine in head and neck cancer.
- Dilution Risk: Review the terms of the Series K notes and warrants (approx. 4.8 million shares) and the April 2007 financing warrants (20 million shares) to understand potential future share count expansion.
- Grant Dependency: Note that grant revenue has ceased; verify if the company has secured new non-dilutive funding sources.